Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel

Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerding, Heinrich, Monés, Jordi, Tadayoni, Ramin, Boscia, Francesco, Pearce, Ian, Priglinger, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/
https://www.ncbi.nlm.nih.gov/pubmed/25075121
http://dx.doi.org/10.1136/bjophthalmol-2014-305041
_version_ 1782359646255710208
author Gerding, Heinrich
Monés, Jordi
Tadayoni, Ramin
Boscia, Francesco
Pearce, Ian
Priglinger, Siegfried
author_facet Gerding, Heinrich
Monés, Jordi
Tadayoni, Ramin
Boscia, Francesco
Pearce, Ian
Priglinger, Siegfried
author_sort Gerding, Heinrich
collection PubMed
description Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment.
format Online
Article
Text
id pubmed-4345884
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43458842015-03-18 Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel Gerding, Heinrich Monés, Jordi Tadayoni, Ramin Boscia, Francesco Pearce, Ian Priglinger, Siegfried Br J Ophthalmol Review Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment. BMJ Publishing Group 2015-03 2014-07-29 /pmc/articles/PMC4345884/ /pubmed/25075121 http://dx.doi.org/10.1136/bjophthalmol-2014-305041 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Review
Gerding, Heinrich
Monés, Jordi
Tadayoni, Ramin
Boscia, Francesco
Pearce, Ian
Priglinger, Siegfried
Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title_full Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title_fullStr Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title_full_unstemmed Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title_short Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
title_sort ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/
https://www.ncbi.nlm.nih.gov/pubmed/25075121
http://dx.doi.org/10.1136/bjophthalmol-2014-305041
work_keys_str_mv AT gerdingheinrich ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel
AT monesjordi ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel
AT tadayoniramin ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel
AT bosciafrancesco ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel
AT pearceian ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel
AT priglingersiegfried ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel